In this five-year placebo-controlled trial involving patients who had a recent stroke or transient ischemic attack and baseline low-density lipoprotein cholesterol levels of 100 to 190 mg per deciliter (3 to 5 mmol per liter), atorvastatin (80 mg daily) resulted in an absolute reduction in nonfatal or fatal stroke of 2.2 percent and of major cardiovascular events of 3.5 percent.

There are now many published examples of gene-expression–based methods to aid in the determination of prognosis, and some of these methods are available to the clinician. This study of five models shows that four of the five classified cancers concordantly, despite minimal overlap in the gene sets used.

This study showed that a predictor based on gene expression provides prognostic information beyond that provided by traditional clinical predictors. It sets the stage for a prospective trial to determine whether the predictor could be used to guide the treatment of patients with stage IA non–small-cell lung cancer.

Among patients with neonatal-onset multisystem inflammatory disease — a disorder characterized by fever, urticarial rash, aseptic meningitis, deforming arthropathy, hearing loss, and mental retardation — treatment with the interleukin-1 antagonist anakinra markedly improved clinical and radiologic manifestations of disease (including central nervous system manifestations) and decreased serum markers of inflammation. Anakinra withdrawal resulted in a flare of disease within days; retreatment led to rapid improvement.